Page 9 - Exscientia News Today

Exscientia (NASDAQ:EXAI – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday, Zacks.com reports. The brokerage currently has a $12.00 price target on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 1.69% from the stock’s current price. […]

Exscientia (NASDAQ:EXAI – Get Rating) issued its earnings results on Wednesday. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10), Fidelity Earnings reports. Shares of NASDAQ EXAI opened at $10.05 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.71 and […]

Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company's pipeline

Exscientia plc This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline,... | May 25, 2022

Company to host conference call and webcast on May 26, 2022 at 1:30 p.m. BST 8:30 a.m. ET Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing

Exscientia (Nasdaq: EXAI) today announced that Ben Taylor, CFO Chief Strategy Officer and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare

Exscientia (NASDAQ:EXAI – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The brokerage presently has a $14.00 price objective on the stock. Zacks Investment Research‘s price target would suggest a potential downside of 7.16% from the […]

Exscientia plc (Nasdaq: EXAI) today shared details of its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13 2022 at the Ernest N. Morial

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development

Shares of Exscientia Ltd (NASDAQ:EXAI – Get Rating) gapped up prior to trading on Tuesday . The stock had previously closed at $13.51, but opened at $14.25. Exscientia shares last traded at $14.50, with a volume of 545 shares. Separately, Zacks Investment Research cut shares of Exscientia from a “buy” rating to a “hold” rating […]